United States Drug Patent 6,280,705: Claim Scope, Expiration, and Ultrasound Microbubble Patent Landscape

U.S. Patent No. 6,280,705 protects reconstitutable ultrasound-contrast kits using a gas osmotic agent, a long-chain phospholipid, and a more water-soluble second surfactant. Its core inventive concept is a dry or powdered precursor that changes shell composition during reconstitution: the second surfactant dissolves or diffuses away, leaving the phospholipid around the gas to form an osmotically stabilized microbubble. The patent covers systems combining the kit with ultrasound equipment and standalone kits, but it does not provide an active U.S. exclusion right today because its patent term has expired.

What does U.S. Patent 6,280,705 protect?

The patent claims a product architecture rather than a broad ultrasound imaging method. The central elements are:

A gas osmotic agent.
A shell-forming first surfactant comprising a phospholipid with at least one acyl chain containing at least 10 carbon atoms.
A second surfactant that is more water soluble than the first surfactant.
Dry microbubble precursors, powdered material, spray-dried microspheres, or lyophilized phospholipid.
Reconstitution with an aqueous medium.
Formation of an osmotically stabilized microbubble.
In some claims, use with an ultrasound imaging apparatus.

The patent’s independent claims are claims 1, 13, and 25.

Independent claim	Claimed subject matter	Primary commercial relevance
Claim 1	Ultrasound imaging system plus a kit capable of producing stabilized microbubbles	Combination of imaging equipment and contrast-agent kit
Claim 13	Kit containing a gas osmotic agent and dry microbubble precursors	Dry or reconstitutable contrast-agent product
Claim 25	Kit containing gas and powdered material, with second-surfactant diffusion during reconstitution	Spray-dried or otherwise powdered formulation

The independent claims are structurally similar. Claims 2-12 depend from claim 1, claims 14-24 depend from claim 13, and claims 26-40 depend from claim 25.

What technical mechanism does the patent claim?

The claimed mechanism is a transient two-surfactant shell system.

The first surfactant is the durable shell-forming component. It must include a phospholipid or phospholipid mixture having at least one acyl chain of 10 or more carbon atoms. The claims specifically identify dimyristoylphosphatidylcholine, or DMPC, and dipalmitoylphosphatidylcholine, or DPPC.

The second surfactant is more water soluble. The claims identify:

Fatty acids and fatty-acid salts
Fatty-acid sugar esters
Polyoxypropylene-polyoxyethylene copolymers
Nonionic alkylglucosides
Polysorbates
Poloxamers

Upon addition of water, the second surfactant facilitates shell dissolution or diffuses from the powdered material. The first surfactant then surrounds the gas osmotic agent. The claimed result is an osmotically stabilized microbubble with improved persistence or stability for ultrasound imaging.

This limitation is important. A formulation containing a phospholipid shell and a fluorinated gas is not automatically within the claims. A potential infringement analysis would need to determine whether the formulation also contains the claimed second, more-water-soluble surfactant and whether the required dry precursor or powder-reconstitution structure is present.

How broad are the gas limitations in U.S. Patent 6,280,705?

The patent claims a large group of perfluorinated compounds. The listed gas osmotic agents include:

Gas category	Examples expressly claimed
Perfluoroalkanes	Perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, perfluoroheptane
Perfluorocycloalkanes	Perfluorocyclobutane, perfluorocyclopentane, perfluorocyclohexane, perfluorocycloheptane
Substituted cyclic compounds	Perfluoromethylcyclobutane, perfluoromethylcyclopentane, perfluoromethylcyclohexane
Fluorinated branched compounds	Perfluorodimethylcyclobutanes, perfluorodimethylcyclopentane, perfluorotrimethylcyclobutane
Fluorinated amine	Perfluorotriethylamine

Dependent claims narrow the gas to perfluoropropane, perfluorobutane, or perfluorohexane. Modifier gases may include nitrogen, oxygen, carbon dioxide, or combinations of those gases.

The gas list is chemically broad but does not eliminate the other limitations. A product using perfluoropropane must still satisfy the claimed shell, surfactant, dry-precursor, and reconstitution requirements.

Which claims are commercially most important?

Claims 13 and 25 are the principal product claims.

Claim 13 is directed to a container holding the gas osmotic agent and dry microbubble precursors. Claim 25 is directed to a container holding the gas and a powdered material that includes both surfactants. Claim 25 also recites the functional event that the second surfactant diffuses from the powdered material when aqueous medium is added.

Claims 31-40 narrow claim 25 toward specific manufacturing and formulation formats:

Spray-dried microspheres
Hydrophilic monomers or polymers
Poloxamers
DMPC or DPPC
Perfluorohexane
Nitrogen as a modifier gas
Lyophilized phospholipid
Perfluorobutane

Claim 1 has narrower practical value because it requires a system containing both an ultrasound imaging apparatus and the kit. Claims 13 and 25 can potentially reach the kit itself without requiring proof that a particular ultrasound device was sold or used with it.

What formulations are protected by U.S. Patent 6,280,705?

The strongest literal claim combinations are formulations with the following profile:

Formulation element	Claim requirement
Gas	Perfluoropropane, perfluorobutane, perfluorohexane, or another listed fluorinated gas
Primary shell surfactant	Phospholipid with at least one acyl chain of 10 or more carbon atoms
Specific phospholipids	DMPC or DPPC in narrower claims
Secondary surfactant	More water-soluble than the primary phospholipid
Secondary examples	Poloxamer, polysorbate, alkylglucoside, fatty-acid derivative, or copolymer
Physical form	Dry precursor, powder, spray-dried microsphere, or lyophilized phospholipid
Use	Reconstitution in an aqueous medium to form stabilized microbubbles
Optional component	Nitrogen, oxygen, or carbon dioxide modifier gas

The claims are less likely to reach a premanufactured liquid microbubble formulation that does not use dry precursors or powder reconstitution. They are also less likely to reach a formulation whose shell is made solely from a phospholipid without the claimed second surfactant.

When did U.S. Patent 6,280,705 lose exclusivity?

U.S. Patent No. 6,280,705 was issued on Aug. 28, 2001. Its term has expired. Public patent records identify the patent as expired, and the 20-year term applicable to the relevant U.S. application family ended before the present date.[1]

Event	Date or status
U.S. patent number	6,280,705
Issue date	Aug. 28, 2001
Patent type	Utility patent
Current U.S. status	Expired
Current enforceable patent term	None
Practical consequence	No new U.S. infringement action can be based solely on this expired patent

The expiration of this patent does not eliminate later patents covering specific ultrasound contrast products, manufacturing processes, delivery systems, clinical indications, or improved formulations.

What is the Orange Book status of U.S. Patent 6,280,705?

U.S. Patent 6,280,705 should not be treated as an active Orange Book barrier. The patent is expired and is not a current source of market exclusivity for ultrasound contrast products.

The FDA-approved products most relevant to this technology include:

Product	Active ingredient or gas	Sponsor or manufacturer	FDA product category
Definity	Perflutren lipid microspheres, using octafluoropropane	Lantheus Medical Imaging	Ultrasound contrast agent
Optison	Perflutren protein-type A microspheres	GE Healthcare	Ultrasound contrast agent
Lumason	Sulfur hexafluoride lipid-type A microspheres	Bracco Diagnostics	Ultrasound contrast agent
Sonazoid	Perflubutane lipid-based microspheres	GE Healthcare in relevant markets	Ultrasound contrast agent

FDA labeling must be reviewed separately for each product because shell composition, gas identity, vial configuration, and approved indications differ.[2-5] The existence of a formulation with a fluorinated gas does not establish coverage by Patent 6,280,705.

How does the patent compare with Definity, Optison, Lumason, and Sonazoid?

Definity and perflutren lipid microspheres

Definity uses perflutren, commonly identified as octafluoropropane, in a lipid shell. Its commercial presentation is a vial-based system activated before administration. Definity is technically close to the patent’s claimed field because it uses a fluorinated gas and a lipid-based shell.

The principal claim-screening questions are whether the commercial formulation contains:

A phospholipid with the claimed acyl-chain limitation;
A distinct second surfactant that is more water soluble;
A dry microbubble precursor or powdered material; and
The claimed reconstitution mechanism.

Similarity in gas or general clinical use is insufficient for a literal infringement conclusion.

Optison

Optison uses perflutren gas in human serum albumin microspheres. Its protein-shell architecture differs materially from the claimed phospholipid-plus-second-surfactant architecture. On the supplied claims, Optison presents a weaker technical overlap than a lipid-shell product.

Lumason

Lumason uses sulfur hexafluoride in lipid-type A microspheres. Sulfur hexafluoride is not among the expressly listed gas osmotic agents in the claims supplied here. A claim analysis would still need to consider doctrine-of-equivalents issues in an active patent context, but those issues have no present enforcement consequence for this expired patent.

Sonazoid

Sonazoid uses perfluorobutane in a lipid-based microbubble formulation. Perfluorobutane is expressly listed in claims 2, 5, 14, 17, 26, and 29. Sonazoid therefore has chemical overlap with the gas limitation. That overlap does not establish claim coverage because the second-surfactant, dry-precursor, and reconstitution limitations remain decisive.

Are there Paragraph IV challenges to U.S. Patent 6,280,705?

No current Paragraph IV challenge has meaningful commercial significance against Patent 6,280,705 because the patent has expired.

A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. An expired patent generally does not block approval or launch. For ultrasound contrast agents, the relevant regulatory pathway may also depend on the product’s FDA classification, formulation, reference product, and whether the product qualifies for an ANDA rather than another application route.

The patent’s expiration means that a generic or competing contrast-agent developer does not need to wait for this patent term to end.

Does biosimilar risk apply to this patent?

Biosimilar risk is not the correct framework for Patent 6,280,705. The patent concerns drug-device systems and microbubble contrast-agent formulations, not a biological molecule subject to the biosimilar provisions of the Public Health Service Act.

Competitive entry would more likely involve:

An ANDA for a pharmaceutically equivalent contrast agent;
A 505(b)(2) application for a modified formulation or delivery system;
A new drug application for a distinct contrast agent; or
A device-drug regulatory strategy for a product supplied with dedicated activation or imaging equipment.

The formulation may contain biologically derived materials, such as albumin in products like Optison, but that fact does not convert the patent into a biosimilar patent.

What manufacturing and intellectual-property barriers remain?

The expired patent no longer creates a blocking U.S. patent right, but manufacturing barriers remain.

Dry-powder production

The patent focuses on spray-dried microspheres, powdered material, and lyophilized phospholipid. Commercial development requires control of:

Particle size distribution;
Residual moisture;
Gas retention;
Reconstitution time;
Microbubble concentration;
Shell integrity;
Sterility and container closure;
Activation energy and reproducibility.

Gas handling

Perfluorinated gases require controlled filling, containment, and analytical testing. Gas composition, headspace volume, pressure, and storage conditions can affect microbubble size and acoustic response.

Product-device integration

The kit claims are relevant to products requiring a vial, diluent, activation device, shaking step, or dedicated administration system. Later patents may protect those components even if the basic dry precursor concept is public-domain technology.

Regulatory comparability

A competing product must establish performance characteristics such as particle size, concentration, acoustic enhancement, pharmacokinetics, safety, and approved imaging indications. FDA labeling for Definity, Optison, and Lumason illustrates the product-specific nature of those requirements.[2-4]

How strong is the patent estate for this technology today?

The estate is historically important but commercially weak as an enforceable U.S. asset because Patent 6,280,705 has expired.

Factor	Assessment
Core technical breadth	Moderate to broad within dry, reconstitutable lipid microbubble systems
Gas coverage	Broad, with extensive perfluorinated-gas enumeration
Formulation specificity	Significant; requires particular surfactant relationships
Manufacturing coverage	Meaningful for spray-dried and lyophilized formats
Product coverage	Potentially relevant to selected lipid-shell products
Current U.S. enforceability	None for this patent
Generic launch barrier	None from Patent 6,280,705 alone
Biosimilar relevance	None
Residual risk	Later patents, regulatory exclusivity, trade secrets, and product-specific claims

What licensing deals or settlements affect this patent?

The patent record and the claim set supplied do not establish a current licensing agreement, Paragraph IV settlement, or enforceable litigation settlement that would restrict use of the claimed technology today. Any historical ownership, assignment, cross-license, or settlement must be evaluated from the USPTO assignment database, court dockets, and transaction documents rather than inferred from the claims.

Because the patent is expired, a historical license may remain relevant to royalty accounting or contractual representations, but it would not restore patent exclusivity.

What generic launch scenarios exist?

A competing company could pursue several routes:

Liquid lipid microsphere product: Lower exposure to the dry-powder limitations, but potentially greater formulation and regulatory differentiation.
Dry or lyophilized phospholipid product: Strongest historical overlap with the patent, but no current infringement barrier from Patent 6,280,705.
Protein-shell product: Technically farther from the claimed phospholipid architecture, as illustrated by Optison.
Alternative gas product: Sulfur hexafluoride or another gas outside the express list may reduce literal overlap, although other patents and regulatory requirements remain relevant.
Perflutren or perfluorobutane product: Greater chemical overlap with the listed gases, but the expired patent does not prevent launch.

Key Takeaways

U.S. Patent 6,280,705 claims dry or powdered ultrasound microbubble precursors that reconstitute into osmotically stabilized lipid-shell microbubbles.
Claims 1, 13, and 25 are the principal independent claims.
The key limitations are a long-chain phospholipid, a more water-soluble second surfactant, a fluorinated gas osmotic agent, and a dry or powdered precursor format.
Perfluoropropane, perfluorobutane, and perfluorohexane are expressly covered in dependent claims.
Definity and Sonazoid have chemical or technical overlap with selected limitations, but product coverage cannot be determined from gas identity alone.
Optison is structurally more distant because it uses an albumin-based shell.
Lumason uses sulfur hexafluoride, which is not among the expressly listed gases in the supplied claims.
Patent 6,280,705 is expired and is not a current U.S. market-exclusivity barrier.
Paragraph IV and biosimilar concerns are not material for this expired patent.
Current competitive risk depends on later patents, FDA exclusivity, manufacturing know-how, device integration, and product-specific regulatory strategy.

Frequently Asked Questions

Can a company sell a dry perfluorobutane ultrasound contrast kit in the United States?

Yes, Patent 6,280,705 alone does not prevent sale because the patent has expired. The product would still require FDA authorization and must be screened against later patents.

Does using DPPC automatically infringe Patent 6,280,705?

No. DPPC is only one claimed phospholipid limitation. The product would also need to be evaluated for the claimed second surfactant, gas, dry precursor, and reconstitution features.

Is perfluoropropane the same as perflutren?

In the ultrasound-contrast context, perflutren is commonly identified with octafluoropropane, a perfluorinated gas. Chemical nomenclature and product labeling should be checked for the specific commercial product.

Does an ultrasound contrast agent need an Orange Book patent listing to be marketed?

No. Orange Book listing affects certain approval and generic-certification processes. It is not a general prerequisite for marketing an FDA-authorized contrast agent.

Can expired Patent 6,280,705 support a patent-infringement lawsuit?

No. An expired patent generally cannot support a new claim for infringement occurring after expiration, although historical disputes may involve damages periods, contractual rights, or related patents.

References

United States Patent and Trademark Office. (2001). U.S. Patent No. 6,280,705, Stabilized microbubble preparations and methods of making same. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Definity (perflutren lipid microsphere) injectable suspension prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Optison (perflutren protein-type A microspheres) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Lumason (sulfur hexafluoride lipid-type A microspheres) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	281183	⤷ Start Trial
Australia	4922196	⤷ Start Trial
Australia	5199701	⤷ Start Trial
Australia	694135	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,280,705

Summary for Patent: 6,280,705